Skip to content
Screener

Ligand Pharmaceuticals LGND Agenus Inc. — Gross carrying value

Similar metrics at other companies

Gentex logo
GNTXOther — Gross carrying value
$38.4M
Arbor Realty Trust logo
ABRAgency Business — Collateral Carrying Value
$442.18M+41.3%
Sirius XM logo
SIRISiriusXM — Gross Carrying Value
$8.61B0.0%
Globe Life logo
GLTexas — Carrying value, gross, percent
15%-2.0pp
Globe Life logo
GLFlorida — Carrying value, gross, percent
19%0.0pp
Globe Life logo
GLAlabama — Carrying value, gross, percent
8%-1.0pp

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept lgnd:FinancialRoyaltyAssetsGross.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemJune 30, 2026 / Gross carrying value(1)June 30, 2026 / AllowanceJune 30, 2026 / Net carrying value (1)December 31, 2025 / Gross carrying value(1)December 31, 2025 / AllowanceDecember 31, 2025 / Net carrying value(1)
Qarziba$101,303$(468)$100,835$118,593$(498)$118,095
Agenus Bot/Bal40,815(408)40,40740,815(408)40,407
Tolerance Therapeutics (Tzield®)25,470(99)25,37125,257(98)25,159
Ohtuvayre inventors19,957(179)19,77816,921(151)16,770
Elutia (CorMatrix)6,062(837)5,2256,607(1,107)5,500
AT2204,442(109)4,3335,132(132)5,000
Primrose mRNA3,281(98)3,1833,281(98)3,183
Zerion2,640(79)2,561

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's agenus inc. — gross carrying value?
Ligand Pharmaceuticals (LGND) reported agenus inc. — gross carrying value of $40.82M in Q2 2026.
What does agenus inc. — gross carrying value mean?
This represents the total historical cost or initial valuation of royalty-based intangible assets associated with the Agenus Inc. partnership before any valuation adjustments. It serves as a baseline measure of the capital investment or acquired value attributed to the specific drug development programs under this license agreement. Tracking this value helps investors understand the scale of the underlying asset portfolio prior to accounting for impairment or amortization.

Ask your AI about Ligand Pharmaceuticals's agenus inc. — gross carrying value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude